• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用超灵敏 ddPCR 方法检测卵巢癌患者诊断和存档液基巴氏样本中的 TP53 突变。

Detecting TP53 mutations in diagnostic and archival liquid-based Pap samples from ovarian cancer patients using an ultra-sensitive ddPCR method.

机构信息

Division of Oncology and Pathology, Department of Clinical Sciences, Skåne University Hospital, Lund University, Lund, Sweden.

Department of Clinical Pathology, Division of Laboratory Medicine, Skåne University Hospital, Lund, Sweden.

出版信息

Sci Rep. 2019 Oct 29;9(1):15506. doi: 10.1038/s41598-019-51697-6.

DOI:10.1038/s41598-019-51697-6
PMID:31664085
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6820715/
Abstract

High-grade serous ovarian cancer (HGSOC) is the most common subtype of epithelial ovarian cancer and early detection is challenging. TP53 mutations are a hallmark of HGSOC and detection of these mutations in liquid-based Pap samples could provide a method for early diagnosis. Here we evaluate the use of IBSAFE, an ultra-sensitive droplet digital PCR (ddPCR) method, for detecting TP53 mutations in liquid-based Pap samples collected from fifteen women at the time of diagnosis (diagnostic samples) and/or up to seven years prior to diagnosis (archival samples). We analysed tumours for somatic TP53 mutations with next generation sequencing and were able to detect the corresponding mutations in diagnostic samples from six of eight women, while one patient harboured a germline mutation. We further detected a mutation in an archival sample obtained 20 months prior to the ovarian cancer diagnosis. The custom designed IBSAFE assays detected minor allele frequencies (MAFs) with very high assay sensitivity (MAF = 0.0068%) and were successful despite low DNA abundance (0.17-206.14 ng, median: 17.27 ng). These results provide support for further evaluation of archival liquid-based Pap samples for diagnostic purposes and demonstrate that ultra-sensitive ddPCR should be evaluated for ovarian cancer screening in high-risk groups or in the recurrent setting.

摘要

高级别浆液性卵巢癌(HGSOC)是上皮性卵巢癌中最常见的亚型,早期检测具有挑战性。TP53 突变是 HGSOC 的标志,在基于液体的巴氏样本中检测这些突变可以提供早期诊断的方法。在这里,我们评估了 IBSAFE 的用途,IBSAFE 是一种超灵敏的液滴数字 PCR(ddPCR)方法,用于检测 15 名女性在诊断时(诊断样本)和/或诊断前长达七年(存档样本)收集的基于液体的巴氏样本中的 TP53 突变。我们使用下一代测序分析肿瘤中的体细胞 TP53 突变,并能够在 8 名女性中的 6 名的诊断样本中检测到相应的突变,而一名患者携带种系突变。我们还在卵巢癌诊断前 20 个月获得的存档样本中检测到一个突变。定制设计的 IBSAFE 检测方法检测到了非常高检测灵敏度(MAF=0.0068%)的小等位基因频率(MAF),尽管 DNA 丰度低(0.17-206.14ng,中位数:17.27ng),但检测仍取得了成功。这些结果为进一步评估存档液体巴氏样本的诊断目的提供了支持,并表明超灵敏 ddPCR 应在高危人群或复发人群中用于卵巢癌筛查进行评估。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/976b/6820715/b05ff0a5a1b7/41598_2019_51697_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/976b/6820715/908947f68c95/41598_2019_51697_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/976b/6820715/b05ff0a5a1b7/41598_2019_51697_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/976b/6820715/908947f68c95/41598_2019_51697_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/976b/6820715/b05ff0a5a1b7/41598_2019_51697_Fig2_HTML.jpg

相似文献

1
Detecting TP53 mutations in diagnostic and archival liquid-based Pap samples from ovarian cancer patients using an ultra-sensitive ddPCR method.利用超灵敏 ddPCR 方法检测卵巢癌患者诊断和存档液基巴氏样本中的 TP53 突变。
Sci Rep. 2019 Oct 29;9(1):15506. doi: 10.1038/s41598-019-51697-6.
2
Characterization of TP53 mutations in Pap test DNA of women with and without serous ovarian carcinoma.分析有和无浆液性卵巢癌的巴氏试验 DNA 中 TP53 突变。
Gynecol Oncol. 2020 Feb;156(2):407-414. doi: 10.1016/j.ygyno.2019.11.124. Epub 2019 Dec 12.
3
Detection of TP53 Clonal Variants in Papanicolaou Test Samples Collected up to 6 Years Prior to High-Grade Serous Epithelial Ovarian Cancer Diagnosis.在高级别浆液性上皮性卵巢癌诊断前长达 6 年收集的巴氏涂片检测样本中检测 TP53 克隆变异。
JAMA Netw Open. 2020 Jul 1;3(7):e207566. doi: 10.1001/jamanetworkopen.2020.7566.
4
Genomic instability analysis in DNA from Papanicolaou test provides proof-of-principle early diagnosis of high-grade serous ovarian cancer.巴氏涂片测试中的 DNA 基因组不稳定性分析为高级别浆液性卵巢癌的早期诊断提供了原理证明。
Sci Transl Med. 2023 Dec 6;15(725):eadi2556. doi: 10.1126/scitranslmed.adi2556.
5
Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in noncancerous tissues.超深度测序可检测腹水中的卵巢癌细胞,并揭示非癌组织中的体细胞TP53突变。
Proc Natl Acad Sci U S A. 2016 May 24;113(21):6005-10. doi: 10.1073/pnas.1601311113. Epub 2016 May 5.
6
Identification of Novel Somatic Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS).采用下一代测序(NGS)技术鉴定高级别浆液性卵巢癌(HGSOC)患者的新型体细胞突变。
Int J Mol Sci. 2018 May 18;19(5):1510. doi: 10.3390/ijms19051510.
7
Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance.使用纯化的卵巢浆液性癌组织样本对TP53突变进行评估,结果显示其突变率高于先前报道,且与耐药性无关。
Int J Gynecol Cancer. 2008 May-Jun;18(3):487-91. doi: 10.1111/j.1525-1438.2007.01039.x. Epub 2007 Aug 10.
8
TP53 mutation in ovarian carcinoma.卵巢癌中的TP53突变
Eur J Cancer. 1997 Jul;33(8):1281-3. doi: 10.1016/s0959-8049(97)00108-1.
9
Targeted Genomic Sequencing Reveals Novel In-frame Deletion Mutations Leading to p53 Overexpression in High-grade Serous Tubo-ovarian Carcinoma.靶向基因组测序揭示导致高级别浆液性输卵管卵巢癌中p53过表达的新型框内缺失突变。
Anticancer Res. 2019 Jun;39(6):2883-2889. doi: 10.21873/anticanres.13417.
10
Single-molecule epiallelic profiling of DNA derived from routinely collected Pap specimens for noninvasive detection of ovarian cancer.从常规收集的巴氏涂片标本中提取的 DNA 进行单分子表观等位基因分析,用于卵巢癌的无创检测。
Clin Transl Med. 2024 Aug;14(8):e1778. doi: 10.1002/ctm2.1778.

引用本文的文献

1
Clinical utility of various liquid biopsy samples for the early detection of ovarian cancer: a comprehensive review.各种液体活检样本在卵巢癌早期检测中的临床应用:一项综述
Front Oncol. 2025 Jul 1;15:1594100. doi: 10.3389/fonc.2025.1594100. eCollection 2025.
2
ctDNA as an Objective Marker for Postoperative Residual Disease in Primary Advanced High-Grade Serous Ovarian Cancer.循环肿瘤DNA作为原发性晚期高级别浆液性卵巢癌术后残留病灶的客观标志物
Cancers (Basel). 2025 Feb 25;17(5):786. doi: 10.3390/cancers17050786.
3
Potential use of DNA methylation in cervical swabs for early ovarian cancer diagnosis.

本文引用的文献

1
Applications of liquid biopsies for cancer.液体活检在癌症中的应用。
Sci Transl Med. 2019 Aug 28;11(507). doi: 10.1126/scitranslmed.aay1984.
2
Ovarian cancer screening-ultrasound; impact on ovarian cancer mortality.卵巢癌筛查——超声检查;对卵巢癌死亡率的影响
Br J Radiol. 2018 Oct;91(1090):20170571. doi: 10.1259/bjr.20170571. Epub 2018 Sep 4.
3
Ovarian cancer statistics, 2018.卵巢癌统计数据,2018 年。
宫颈拭子中DNA甲基化在早期卵巢癌诊断中的潜在应用。
J Ovarian Res. 2025 Feb 15;18(1):29. doi: 10.1186/s13048-025-01609-2.
4
Optimization of Pre-Analytical Handling to Maintain DNA Integrity in Diagnostic Papanicolaou Tests.优化分析前处理以维持诊断性巴氏试验中的DNA完整性
J Mol Diagn. 2025 Mar;27(3):199-208. doi: 10.1016/j.jmoldx.2024.12.008. Epub 2025 Jan 17.
5
Cervicovaginal specimen biomarkers for early detection of ovarian and endometrial cancer: A review.宫颈阴道标本生物标志物在卵巢癌和子宫内膜癌早期检测中的应用:综述。
Cancer Med. 2024 Jul;13(14):e70000. doi: 10.1002/cam4.70000.
6
TP53 somatic evolution in cervical liquid-based cytology and blood from individuals with and without ovarian cancer and BRCA1 or BRCA2 germline mutations.在有和没有卵巢癌以及 BRCA1 或 BRCA2 种系突变的个体的宫颈液基细胞学和血液中检测 TP53 体细胞进化。
Oncogene. 2024 Jul;43(31):2421-2430. doi: 10.1038/s41388-024-03089-y. Epub 2024 Jun 25.
7
Comprehensive clinical assays for molecular diagnostics of gliomas: the current state and future prospects.神经胶质瘤分子诊断的综合临床检测:现状与未来前景
Front Mol Biosci. 2023 Oct 16;10:1216102. doi: 10.3389/fmolb.2023.1216102. eCollection 2023.
8
Current and Emerging Applications of Droplet Digital PCR in Oncology: An Updated Review.液滴数字PCR在肿瘤学中的当前及新兴应用:最新综述
Mol Diagn Ther. 2022 Jan;26(1):61-87. doi: 10.1007/s40291-021-00562-2. Epub 2021 Nov 13.
9
Droplet digital polymerase chain reaction for detection and quantification of cell-free DNA TP53 target somatic mutations in oral cancer.液滴数字聚合酶链反应检测和定量口腔癌游离 DNA TP53 靶基因突变。
Cancer Biomark. 2022;33(1):29-41. doi: 10.3233/CBM-210275.
10
The G199X and V157fs mutations in the gene promote malignancy in serous ovarian cancer: an analysis using whole-exome sequencing.该基因中的G199X和V157fs突变促进浆液性卵巢癌的恶性发展:一项使用全外显子组测序的分析。
Ann Transl Med. 2021 Apr;9(8):710. doi: 10.21037/atm-21-583.
CA Cancer J Clin. 2018 Jul;68(4):284-296. doi: 10.3322/caac.21456. Epub 2018 May 29.
4
A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers.妇科和乳腺癌的全面泛癌分子研究。
Cancer Cell. 2018 Apr 9;33(4):690-705.e9. doi: 10.1016/j.ccell.2018.03.014. Epub 2018 Apr 2.
5
Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers.巴氏涂片检查和其他液体活检测试在子宫内膜癌和卵巢癌检测中的评估。
Sci Transl Med. 2018 Mar 21;10(433). doi: 10.1126/scitranslmed.aap8793.
6
Screening for Ovarian Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.卵巢癌筛查:美国预防服务工作组的更新证据报告和系统评价。
JAMA. 2018 Feb 13;319(6):595-606. doi: 10.1001/jama.2017.21421.
7
An optimized targeted Next-Generation Sequencing approach for sensitive detection of single nucleotide variants.一种用于灵敏检测单核苷酸变异的优化靶向新一代测序方法。
Biomol Detect Quantif. 2018 Jan 9;15:6-12. doi: 10.1016/j.bdq.2017.12.001. eCollection 2018 May.
8
High grade serous ovarian carcinomas originate in the fallopian tube.高级别浆液性卵巢癌起源于输卵管。
Nat Commun. 2017 Oct 23;8(1):1093. doi: 10.1038/s41467-017-00962-1.
9
Multiplex quantification of four DNA targets in one reaction with Bio-Rad droplet digital PCR system for GMO detection.使用伯乐液滴数字PCR系统在一个反应中对四个DNA靶标进行多重定量以检测转基因生物。
Sci Rep. 2016 Oct 14;6:35451. doi: 10.1038/srep35451.
10
Detecting Circulating Tumor DNA in Hepatocellular Carcinoma Patients Using Droplet Digital PCR Is Feasible and Reflects Intratumoral Heterogeneity.使用液滴数字PCR检测肝细胞癌患者循环肿瘤DNA是可行的,且能反映肿瘤内异质性。
J Cancer. 2016 Sep 13;7(13):1907-1914. doi: 10.7150/jca.15823. eCollection 2016.